Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ANPEP | P15144 | 2/20 | 0.59 |
| ▸ | TAS1R3 | Q7RTX0 | 5/20 | 0.55 |
| ▸ | TAS1R1 | Q7RTX1 | 5/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | MMP1 | P03956 | 3/20 | 0.46 |
| ▸ | MMP3 | P08254 | 1/20 | 0.46 |
| ▸ | MMP9 | P14780 | 1/20 | 0.46 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | CTSK | P43235 | 1/20 | 0.46 |
| ▸ | CASR | P41180 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24446769 | 1.00 | ANPEP (0.59) | ANPEPTAS1R3TAS1R1ALDH1A1NPC1 | |
| SCHEMBL24446771 | 0.88 | ANPEP (0.59) | ANPEPTAS1R3TAS1R1ALDH1A1NPC1 | |
| SCHEMBL1871252 | 0.87 | ANPEP (0.57) | ANPEPTAS1R3TAS1R1ALDH1A1NPC1 | |
| SCHEMBL6158798 | 0.86 | CTSK (0.47) | ANPEPTAS1R3TAS1R1MMP9CTSK | |
| SCHEMBL6158794 | 0.86 | CTSK (0.47) | ANPEPTAS1R3TAS1R1MMP9CTSK | |
| SCHEMBL21301600 | 0.85 | PPID (0.57) | ANPEPTAS1R3TAS1R1CTSK | |
| SCHEMBL3955674 | 0.85 | NOS3 (0.55) | ANPEPTAS1R3TAS1R1MEN1KMT2A | |
| SCHEMBL3957241 | 0.85 | NOS3 (0.55) | ANPEPTAS1R3TAS1R1MEN1KMT2A | |
| SCHEMBL3955671 | 0.85 | NOS3 (0.55) | ANPEPTAS1R3TAS1R1MEN1KMT2A | |
| SCHEMBL6129757 | 0.85 | ATM (0.54) | ANPEPTAS1R3TAS1R1ALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112142655-A | Biaryl kinase inhibitors | 百时美施贵宝公司 | 2020-12-29 | — | — | CN | disclosed |
| CN-108368084-B | Biaryl kinase inhibitors | 百时美施贵宝公司 | 2020-10-16 | — | — | CN | disclosed |
| US-10544120-B2 | Biaryl kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-01-28 | — | — | US | disclosed |
| US-10544120-B2 | Biaryl kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-01-28 | — | — | US | disclosed |
| EP-3356340-B1 | BIARYL KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2019-10-23 | — | — | EP | disclosed |
| EP-3356340-B1 | BIARYL KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2019-10-23 | — | — | EP | disclosed |
| US-20180346440-A1 | BIARYL KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2018-12-06 | — | — | US | disclosed |
| EP-3356340-A1 | BIARYL KINASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2018-08-08 | — | — | EP | disclosed |
| CN-108368084-A | Biaryl kinase inhibitors | 百时美施贵宝公司 | 2018-08-03 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180346440-A1 | BIARYL KINASE INHIBITORS | AAK1, CAMKK1, CAMKK2 | ANPEP 3895/4885TAS1R3 3894/4885TAS1R1 3980/4885 |
| US-10544120-B2 | Biaryl kinase inhibitors | AAK1, CAMKK1, CAMKK2 | ANPEP 3895/4885TAS1R3 3894/4885TAS1R1 3980/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.